Sandeep Jagtap: Presenting the Research Behind Pediatric Fondaparinux at ISTH 2026
Sandeep Jagtap, Senior Director, Global Clinical Strategy and Innovation at Viatris, shared a post on LinkedIn:
“Some scientific moments stay with you for a long time.
It was truly special to present one of our most cherished pieces of work at ISTH 2026 in Paris. This research on Arixtra (fondaparinux) contributed to its FDA approval for pediatric venous thromboembolism patients, helping address an area of significant unmet medical need.
Presenting this work on such a prestigious global platform was both humbling and deeply rewarding.
I am sincerely grateful to all the colleagues, investigators, and collaborators whose dedication and contributions made this work possible. It was a proud and memorable moment to see years of collective effort translated into meaningful progress for children.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand